Novo Nordisk supports endocrine society to ensure better treatment
Economic Reporter :
Diabetic Association of Bangladesh and Bangladesh Endocrine Society jointly organized the 21st Endocrine Conference to share knowledge among the country’s healthcare professionals.
Novo Nordisk supported endocrine society to organise a number sessions on how to ensure better treatment for patients living with diabetes with original products.
“We want to help enhance physicians’ knowledge to meet the county’s dire need of diabetic care”, said Managing Director of Novo Nordisk A Rajan Kumar.
Dr. Mohammad Saiful, Head of Marketing of Novo Nordisk said, “We always try to help healthcare professionals to get the latest treatment option with relevant data once it is released in the global healthcare industry.”
Some important sessions, Changing Diabetes® Barometer outcome dissemination and workshop on trust the original, were organised by Novo Nordisk.
Dr. Nazmul Kabir Qureshi, Specialist on Medicine and Endocrinology, United Hospital, said for better treatment outcome patients living with diabetes should go with original product, while presenting on originator insulin cannot be interchanged with biosimilar insulin.
Novo Nordisk is the only company in Bangladesh with entire range of product portfolio as it has responsibility towards society to provide better treatment option for better management of diabetes.
Novo Nordisk is doing business following triple bottom line philosophy that made it liable to society and environment.
Professor Dr. Liaquat Ali, Vice Chancellor, Bangladesh University of Health Science, said: “Diabetes emerges as epidemic in the world. In Bangladesh 90 lakh people living with diabetes, therefore, endocrine conference is an important platform for all patients, doctors and nurses to share knowledge on diabetes to ensure better treatment.”
Professor Dr. Khwaja Nazimuddin, Medicine, BIRDEM Hospital, said: “Endocrine conference is a good platform for us to earn more knowledge on next generation diabetes treatments.”
He also said Ryzodeg® offers successful reductions in blood glucose with lower risk of hypoglycaemia compared to conventional insulins for adults with type 2diabetes.
Dr. Kalyan Kumar Gangopadhyay, Endocrinology Consultant, Fortis Hospital in India, said, endocrine conference is a platform for endocrinologist to exchange more knowledge on updated treatment options for diabetes.
Dr. SM Ashrafuzzaman, Associate Professor, Dept. of Endocrinology, BIRDEM Hospital, said the conference has been opened a new window of opportunity to know more on modern and next generation insulins.
Diabetic Association of Bangladesh and Bangladesh Endocrine Society jointly organized the 21st Endocrine Conference to share knowledge among the country’s healthcare professionals.
Novo Nordisk supported endocrine society to organise a number sessions on how to ensure better treatment for patients living with diabetes with original products.
“We want to help enhance physicians’ knowledge to meet the county’s dire need of diabetic care”, said Managing Director of Novo Nordisk A Rajan Kumar.
Dr. Mohammad Saiful, Head of Marketing of Novo Nordisk said, “We always try to help healthcare professionals to get the latest treatment option with relevant data once it is released in the global healthcare industry.”
Some important sessions, Changing Diabetes® Barometer outcome dissemination and workshop on trust the original, were organised by Novo Nordisk.
Dr. Nazmul Kabir Qureshi, Specialist on Medicine and Endocrinology, United Hospital, said for better treatment outcome patients living with diabetes should go with original product, while presenting on originator insulin cannot be interchanged with biosimilar insulin.
Novo Nordisk is the only company in Bangladesh with entire range of product portfolio as it has responsibility towards society to provide better treatment option for better management of diabetes.
Novo Nordisk is doing business following triple bottom line philosophy that made it liable to society and environment.
Professor Dr. Liaquat Ali, Vice Chancellor, Bangladesh University of Health Science, said: “Diabetes emerges as epidemic in the world. In Bangladesh 90 lakh people living with diabetes, therefore, endocrine conference is an important platform for all patients, doctors and nurses to share knowledge on diabetes to ensure better treatment.”
Professor Dr. Khwaja Nazimuddin, Medicine, BIRDEM Hospital, said: “Endocrine conference is a good platform for us to earn more knowledge on next generation diabetes treatments.”
He also said Ryzodeg® offers successful reductions in blood glucose with lower risk of hypoglycaemia compared to conventional insulins for adults with type 2diabetes.
Dr. Kalyan Kumar Gangopadhyay, Endocrinology Consultant, Fortis Hospital in India, said, endocrine conference is a platform for endocrinologist to exchange more knowledge on updated treatment options for diabetes.
Dr. SM Ashrafuzzaman, Associate Professor, Dept. of Endocrinology, BIRDEM Hospital, said the conference has been opened a new window of opportunity to know more on modern and next generation insulins.
